Transplantation in Lymphoma

Transplantation in Lymphoma

Dr Adrian BloorTransplant Director

The Christie NHS Foundation Trust

NHSNHS

Are you a believer?

The Christie NHS Foundation Trust

NHSNHS

Transplant Outcomes

The Christie NHS Foundation Trust

NHSNHS

Summary

• A big subject in 20 mins

• Briefly review rationale for transplantation

• Autografting Historical results and place in current treatment

New data in DLBCL, MCL

• Allografting Follicular NHL

Hodgkin Lymphoma

The Christie NHS Foundation Trust

NHSNHS

Autologous Transplantation

The Christie NHS Foundation Trust

NHSNHS

Dose intensity

Cou

nt

Time

Blood countDisease

Cou

nt

The Christie NHS Foundation Trust

NHSNHS

Autologous Transplantation

Indication TrialMedian PFS

months

OS

months

Relapsed FL CUP >36 vs 12 NR vs 46

Transformed FL EBMT NS (vs controls) NS (vs controls)

MCL MCL Network 39 vs 17 NS

Relapsed DLBCL PARMA >48 vs <12 NR vs 15

Relapsed HL BNLI/GHDSG >36 vs <12 NS

Williams CD et al J Clin Oncol 2001;19:727Shouten HC et al J Clin Oncol 2003;21:3918Dreyling M et al Blood 2005;105:2677Philip T et al N Engl J Med 1995;333:1540Schmitz N et al Lancet 2002;359:2065Linch DC et al Lancet 1993;341:8852

The Christie NHS Foundation Trust

NHSNHS

CORAL - DLBCL

Gisselbrecht C et al J Clin Oncol 2009;27:8509a

n = 396• Response rate 63% • Relapse < 12 months (46% vs 88%) • Prior Rituxumab (51% vs 83%)

Relapsed DLBCL

R-ICE

R-DHAP

BEAM

RANDOMISE

Observe

R maint

RANDOMISE

The Christie NHS Foundation Trust

NHSNHS

CORAL - DLBCL

n = 123

3 year OS/EFS 47/30%

PET –ve

OS 66%EFS 40%

Trneny M et al Blood 2009;114:881a

The Christie NHS Foundation Trust

NHSNHS

CORAL - DLBCL

n = 123

3 year OS/EFS 47/30%

PET –ve

OS 66%EFS 40%

PET +ve

OS 49%EFS 16%

p = sig

Trneny M et al Blood 2009;114:881a

The Christie NHS Foundation Trust

NHSNHS

Mantle Cell Lymphoma - Nordic

n = 41

ORR 75% CR 27%

4 yr PFS 15%

n = 160

ORR 96% CR 54%

6 yr PFS 66%

NRM 5%

Z-BEAM (no CR)

MCL 32006-2009

n = 160

ORR 96% CR 68%

NRM 4%

maxi-CHOPx4

BEAM(C) auto

MCL 11996-2000

R-maxi-CHOP /R-HD-AraC x6

Purged BEAM(C) auto

R

MCL 22000-2006

Andersen NC et al Eur J Haematol 2003;71:73 Geisler CH et al Blood 2008;112:2687 Kolstad A et al Blood 2009;114:932a

The Christie NHS Foundation Trust

NHSNHS

Autograft mortality 1998-2002

SUM05_20.ppt

Infection (6%)

Other (9%)

Organ toxicity (8%)Relapse (75%)

Unknown (2%)

The Christie NHS Foundation Trust

NHSNHS

Allogeneic Transplantation

derived from Bortin MM Transplantation 1970;9:571

The Christie NHS Foundation Trust

NHSNHS

Beneficial effect of GvHD

Horowitz MM et al Blood 1990;75:555

The Christie NHS Foundation Trust

NHSNHS

RECIPIENT DONOR

GvD

GvHD and GvDisease

The Christie NHS Foundation Trust

NHSNHS

RECIPIENT DONOR

GvD

GvHD and GvDisease

The Christie NHS Foundation Trust

NHSNHS

GvHD and GvDisease

0.00001

0.0001

0.001

0.01

0.1

1

Jun-09 Sep-09 Dec-09 Mar-10 Jun-10 Sep-10

Chemo SCT

CSA

The Christie NHS Foundation Trust

NHSNHS

Follicular NHL

Series Follow up n Protocol PFS/OS NRMExtensive

cGvHD

UCLH 43 mo 82 FMC90% (sib)

64% (UD)

8% (sib)

22% (UD)18%

MDACC 60 mo 43 FCR 85% 16% 36%

Thomson KJ et al J Clin Oncol 2010;28:3695Khouri IF et al Blood 2008;111:5530

Montoto S et al Leukemia 2007;21:2324

Replacement for autograft?

The Christie NHS Foundation Trust

NHSNHS

HL: Winners and Losers

The Christie NHS Foundation Trust

NHSNHS

HL: Salvage autografts

Schmitz N et al Lancet 2002;359:2065Linch DC et al Lancet 1993;341:8852

The Christie NHS Foundation Trust

NHSNHS

MSKCC

• 71 patients (1994-2005)• Poor prognosis• Second transplant improves

outcome

And if it doesn’t work?

Moskowitz AJ Br J Haematol 2009;146:158

The Christie NHS Foundation Trust

NHSNHS

AlloHSCT for poor prognosis?

The Christie NHS Foundation Trust

NHSNHS

AlloHSCT for poor prognosis?

Milied N et al J Clin Oncol 1996;14:1291

EMBT matched pair series

• 90 patients• >50% refractory relapse• 2 yr NRM >50% (allo) vs 12% (auto)

But..

• GvHD appears beneficial• Relapse rate 13% (allo) vs 69% (auto)

The Christie NHS Foundation Trust

NHSNHS

RIC Allo outcome

Centre nPrior HDT

RefractoryPFS

(2-4 yr)

OS

(2-4 yr)

EBMT 401 67% 22% 26% (3 yr) 41% (3yr)

Single Centre

32-5871-

100%33-50% 8-39% 32-64%

NRM 12-46% Age, PS, date of transplant

Robinson SP et al Haematologica 2009;94:230

The Christie NHS Foundation Trust

NHSNHS

Pick a winner

TTF – based on prognostic score

• PS• Disease Status• Chemosensitivity• Remission duration• Tumour bulk • Extranodal disease

eg Stanford series

Johnston LJ et al Biol Blood Marrow Trans 2000;6:289

0

1

32

The Christie NHS Foundation Trust

NHSNHS

Pick a winner

Patient A Patient B

The Christie NHS Foundation Trust

NHSNHS

Risk Stratification by FI

Centre n Technique3 yr EFS

PET +ve

3 yr EFS

PET -ve

MDACC 21168 PET 174 Ga

27%52% (PR)

77% (CR)

MSKCC 16050 PET 110 Ga

33% 74%

Jabbour E et al Cancer 2007;109:2481Moskowitz C unpublished

The Christie NHS Foundation Trust

NHSNHS

Trials

The Christie NHS Foundation Trust

NHSNHS

Trials designed

ReACH

• Chemosensitive PET +ve second remission

• Siblings donors

PAIReD

• Chemorefractory (PET) first or second remission

• Matched donors

The Christie NHS Foundation Trust

NHSNHS

Patient Selection

Extermann M et al Eur J Can 2000;36:453Havlik R et al Cancer 1994;74(s7):2101http://seer.cancer.gov/

Comorbidities by age

0

20

40

60

80

100

55-64 65-74 75+

Age range / yearsF

requ

ency

/ %

≤1 2-4 ≥5

0

100

0 20 40 60 80Age

Inci

denc

e / 1

00,0

00

The Christie NHS Foundation Trust

NHSNHS

Conclusions

• A big subject in 20 mins

• Autologous transplant effective treatment for many patients with relapsed disease

• Autografts have no potential for cure

• Allogeneic effect exists in lymphoma

• Allogeneic transplantation remains developmental in most areas

• Ongoing trials in progress

• Patient selection essential – but how?